EICHORCondition: Advanced Solid Tumors · Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS107 monotherapy and combination with Toripalimab in patients with Advanced or Metastatic Solid Tumors.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| The People's Hospital of Chizhou | Chizhou, Anhui, China | — |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | — |
| Gansu Wuwei Tumour Hospital | Wuwei, Gansu, China | — |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | — |
| Meizhou People's Hospital | Meizhou, Guangdong, China | — |
| The Fourth Hospital of Hebei Medical University | Shijiazhuang, Hebei, China | — |
| Wuhan University People's Hospital | Wuhan, Hebei, China | — |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | — |
| Anyang Tumor Hospital | An'yang, Henan, China | — |
| The First Affiliated Hospital of Henan University of Science and Technology | Luoyang, Henan, China | — |
| The First Affiliated Hospital of Xinxiang Medical University | Xinxiang, Henan, China | — |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | — |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05502393